Preclinical data showed that targeting mTOR along with antiandrogen treatment exhibited additive antitumor effects in a prostate-specific Pten (pseudogene of the tumor suppressor)-deleted mouse model, supporting the rationale for combining AR and mTOR inhibitors to treat CRPC [95]. The gene discussed is AR; the disease is neoplasm.